Drug Profile

OLX 104C

Alternative Names: OLX-104C

Latest Information Update: 28 Mar 2025

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator OliX Pharmaceuticals
Class Skin disorder therapies; Small interfering RNA
Mechanism of Action RNA interference

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes
Available For Licensing Yes - Alopecia

Highest Development Phases

No development reported Alopecia

Most Recent Events

28 Mar 2025 No recent reports of development identified for preclinical development in Alopecia in South Korea (Topical)
22 Nov 2022 OliX Pharmaceuticals plans to submit a Human Research Ethics Application (HREA) for phase I trial for Alopecia by end of 2022
22 Nov 2022 Pharmacodynamics data from preclinical study in Alopecia released by OliX Pharmaceuticals

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com